Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allied BiotechROCO:1780 -1.76%77 PB Ratio is 1.74 as of Jul. 20, 2026, which is 19% above its 10-year median of 1.46. GuruFocus rates ROCO:1780 with a GF Score™ of 77/100 and a GF Value™ of NT$20.78 (Fairly Valued). The stock has 5 warning signs investors should review. Among 924 Drug Manufacturers companies, Allied Biotech ranks better than 53.68% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-20), Allied Biotech's share price is NT$22.30. Allied Biotech's Book Value per Share for the quarter that ended in Dec. 2025 was NT$12.83. Hence, Allied Biotech's PB Ratio of today is 1.74.
The historical rank and industry rank for Allied Biotech's PB Ratio or its related term are showing as below:
ROCO:1780'
s PB Ratio Range Over the Past 10 Years
Min: 1.1 Med: 1.46 Max: 2.61
Current: 1.74
During the past 13 years, Allied Biotech's highest PB Ratio was 2.61. The lowest was 1.10. And the median was 1.46.
ROCO:1780's PB Ratio is ranked better than 53.68% of 924
companies
in the Drug Manufacturers industry
Industry Median: 1.895
vs ROCO:1780: 1.74
During the past 12 months, Allied Biotech's average Book Value Per Share Growth Rate was 3.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 1.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 1.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Allied Biotech was 5.50% per year. The lowest was -1.80% per year. And the median was 1.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Allied Biotech PB Ratio Related Terms
Allied Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for Allied Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Allied Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allied Biotech PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allied Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Allied Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Allied Biotech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Allied Biotech (ROCO:1780) has a PB Ratio of 1.74 as of Jul. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Allied Biotech and its competitors. This is 19% above median its historical median of 1.46. Over the past decade, Allied Biotech's PB Ratio has ranged from 1.10 to 2.61. According to the industry distribution chart, Allied Biotech ranks #428 out of 924 companies in the Drug Manufacturers industry, placing it in the top 46.3%.
Is Allied Biotech's PB Ratio too high?
Allied Biotech's current PB Ratio of 1.74 is 19% above median its 10-year median of 1.46. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 2.61. The Drug Manufacturers industry median PB Ratio is 1.90. Allied Biotech's value of 1.74 is 8.2% below this industry median. Based on the distribution chart, Allied Biotech ranks #428 out of 924 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Allied Biotech has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Allied Biotech's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allied Biotech ranks #428 out of 924 companies for PB Ratio. This puts Allied Biotech in the upper half of its industry. The industry median PB Ratio is 1.90. Allied Biotech's value of 1.74 is 8.2% below this benchmark. Historically, Allied Biotech's own PB Ratio has ranged from 1.10 to 2.61 over the past decade. While the company's 10-year median is 1.46 vs. the industry median of 1.90, Allied Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allied Biotech's current PB Ratio of 1.74 is 8.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Allied Biotech and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allied Biotech's current PB Ratio is 1.74, which is 19% above median its own 10-year median of 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied Biotech stock overvalued right now?
Based on GuruFocus' analysis, Allied Biotech (ROCO:1780) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.78, compared to a current price of NT$22.30 — trading 7.3% above its estimated fair value. The current PB Ratio is 1.74, which is 19% above median its 10-year median of 1.46 and 8.2% below the Drug Manufacturers industry median of 1.90. Allied Biotech's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Allied Biotech (ROCO:1780), the current PB Ratio is 1.74 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allied Biotech (ROCO:1780) Overvalued in 2026?
Based on GuruFocus' analysis, Allied Biotech stock appears to be overvalued.
The current stock price of NT$22.30 is trading 7.3% above its estimated GF Value™ of NT$20.78.
GuruFocus considers Allied Biotech to be Fairly Valued.
Key valuation signals for ROCO:1780:
PB Ratio: 1.74 (19% above median its 10-year median of 1.46)
GF Value™: NT$20.78 vs. price of NT$22.30 (7.3% above fair value)
Industry Position: 8.2% below the Drug Manufacturers median (#428 of 924)
No single metric tells the full story. See the ROCO:1780 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allied Biotech Corp is a Taiwan based manufacturer of carotenoids. It manufactures carotenoid formulations for the food, supplement and feed industries. The company markets its products under the name Altratene.
77GF Score
Get the complete analysis for ROCO:1780
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1780 has been successfully added to your 
